Nature of Business (Details) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Feb. 28, 2019	Mar. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Nature of Business (Details) [Line Items]
Contracts from NIH and NIAID, description			The Company is currently developing RiVax® under a NIAID contract of up to $21.2 million over six years, a one-year NIH grant of $150,000 in support of its SGX942 pediatric program and a two year $1.5M NIH grant to support manufacture, formulation (including thermostabilization) and characterization of COVID-19 and Ebola Virus Disease vaccine candidates in conjunction with the CoVaccine HT™ adjuvant. In addition, the Company has a subcontract of approximately $700,000 from a NIAID grant over five years for its thermostabilization technology, and a DTRA subcontract of approximately $600,000 over three years for SGX943.
Accumulated deficit			$ 193,214,134
Net loss			(17,688,522)	$ (9,355,592)
Cash in operating activities			11,454,426
Common stock issued (in Shares)	78,338
Cash and cash equivalents			18,676,663	5,420,708	$ 8,983,717
Increase of cash and cash equivalents			$ 13,255,955
Percentage change in cash and cash equivalent			245.00%
Working capital			$ 13,386,485	$ 1,181,249
Increase in cash and cash equivalents			$ 12,205,236
Liquidity management, description			● The Company has up to $2.16 million in active government contract and grant funding still available as of December 31, 2020 to support its associated research programs through 2022 and beyond, provided the federal agencies do not elect to terminate the contracts or grants for convenience.
Remaining from FBR sales agreement, description			However, there can be no assurances that the Company can consummate such transactions; ● The Company has up to $10.0 million remaining available from the loan and security agreement with Pontifax Medison Finance as of March 30, 2021, which includes an immediately available $5 million line of credit and a $5 million late withdrawal loan that is contingent upon the initial filing of the NDA for CTCL; ● The Company has up to $2.1 million remaining from the FBR Sales Agreement as of March 30, 2021 under the prospectus supplement updated August 28, 2020
Subsequent Event [Member]
Nature of Business (Details) [Line Items]
Common stock issued (in Shares)		9,376,792
Weighted average price per share (in Dollars per share)		$ 1.75